FRI0001 Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation

Giulio Cavalli; Marije I. Koenders; J. Kim; Aik Choon Tan; Cecília Garlanda; Alberto Mantovani; Lorenzo Dagna; Leo A. B. Joosten; C A Dinarello

doi:10.1136/annrheumdis-2016-eular.2713

Related publications

Article2016

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

Giulio Cavalli, Marije I. Koenders, Vassili Kalabokis, Ji Hye Kim, Aik Choon Tan, Cecília Garlanda, Alberto Mantovani, Lorenzo Dagna, Leo A. B. Joosten, Charles A. Dinarello

Corrigendum2017

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

Giulio Cavalli, Marije Koenders, Vassili Kalabokis, Jihye Kim, Aik Choon Tan, Cecília Garlanda, Alberto Mantovani, Lorenzo Dagna, Leo A. B. Joosten, Charles A. Dinarello

Article2015

Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8

Suzhao Li, C. Preston Neff, Kristina Barber, Jaewoo Hong, Yuchun Luo, Tania Azam, Brent E. Palmer, Mayumi Fujita, Cecília Garlanda, Alberto Mantovani, Soohyun Kim, Charles A. Dinarello

Article2005

IL‐18 is redundant in T‐cell responses and in joint inflammation in antigen‐induced arthritis

Leilani L. Santos, Georgia Milenkovski, Pamela Hall, Michelle Leech, Laveena Sharma, Kiyoshi Takeda, Akira Shizuo, A. Richard Kitching, Eric F. Morand

Immunology and Cell Biology

Article2015

IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction

Claudia A. Nold‐Petry, Camden Lo, Ina Rudloff, Kirstin Elgass, Suzhao Li, Michael P. Gantier, Amelie S. Lotz‐Havla, Søren W. Gersting, Steven Cho, Jason Chun Lao, Andrew M. Ellisdon, Björn Rotter, Tania Azam, Niamh E. Mangan, Fernando J. Rossello, James C. Whisstock, Philip Bufler, Cecília Garlanda, Alberto Mantovani, Charles A. Dinarello, Marcel F. Nold

FRI0001 Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation

Discussion(0)

Related publications

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8

IL‐18 is redundant in T‐cell responses and in joint inflammation in antigen‐induced arthritis

IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction